Enliven Therapeutics annual shareholders’ equity
2019
2020
2021
2022
2023
2024
2025
Enliven Therapeutics Shareholders’ Equity Growth & History (ELVN)
Enliven Therapeutics's shareholders’ equity was $459.6M for fiscal 2025.
View full Enliven Therapeutics company overviewEnliven Therapeutics annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $459.6M | $149.8M | +48.33% |
| 2024 | 2024-12-31 | $309.8M | $63.9M | +26.00% |
| 2023 | 2023-12-31 | $245.9M | $322.7M | — |
| 2022 | 2022-12-31 | −$76.8M | −$33.9M | — |
| 2021 | 2021-12-31 | −$42.9M | −$127.3M | — |
| 2020 | 2020-12-31 | $84.4M | $133.3M | — |
| 2019 | 2019-12-31 | −$48.8M | — | — |
Enliven Therapeutics quarterly shareholders’ equity
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $895.1M | $406.7M | +83.25% |
| Q1 2026 | 2026-03-31 | $453.4M | $165.1M | +57.26% |
| Q4 2025 | 2025-12-31 | $459.6M | $149.8M | +48.33% |
| Q3 2025 | 2025-09-30 | $476.1M | $187.7M | +65.09% |
| Q2 2025 | 2025-06-30 | $488.5M | $183.5M | +60.19% |
| Q1 2025 | 2025-03-31 | $288.3M | −$29.4M | −9.26% |
| Q4 2024 | 2024-12-31 | $309.8M | $63.9M | +26.00% |
| Q3 2024 | 2024-09-30 | $288.4M | $26.7M | +10.18% |
| Q2 2024 | 2024-06-30 | $304.9M | $25.9M | +9.30% |
| Q1 2024 | 2024-03-31 | $317.7M | $26.3M | +9.02% |
| Q4 2023 | 2023-12-31 | $245.9M | $322.7M | — |
| Q3 2023 | 2023-09-30 | $261.7M | $329.8M | — |
| Q2 2023 | 2023-06-30 | $279.0M | $337.7M | — |
| Q1 2023 | 2023-03-31 | $291.4M | $342.0M | — |
| Q4 2022 | 2022-12-31 | −$76.8M | −$33.9M | — |
| Q3 2022 | 2022-09-30 | −$68.1M | −$167.5M | — |
| Q2 2022 | 2022-06-30 | −$58.7M | −$123.7M | — |
| Q1 2022 | 2022-03-31 | −$50.6M | −$126.2M | — |
| Q4 2021 | 2021-12-31 | −$42.9M | −$127.3M | — |
| Q3 2021 | 2021-09-30 | $99.4M | $4.7M | +4.94% |
| Q2 2021 | 2021-06-30 | $65.0M | −$41.3M | −38.88% |
| Q1 2021 | 2021-03-31 | $75.6M | −$29.6M | −28.14% |
| Q4 2020 | 2020-12-31 | $84.4M | $133.3M | — |
| Q3 2020 | 2020-09-30 | $94.7M | — | — |
| Q2 2020 | 2020-06-30 | $106.3M | — | — |
| Q1 2020 | 2020-03-31 | $105.2M | — | — |
| Q4 2019 | 2019-12-31 | −$48.8M | — | — |
Enliven Therapeutics shareholders’ equity trends
Over the last five fiscal years, Enliven Therapeutics's shareholders’ equity increased from $84.4M to $459.6M, a change of $375.2M. The latest reported quarter, Q2 2026, shows $895.1M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Enliven Therapeutics source filings ↗